Mark Lustberg, PhD, MD
Associate Professor of Internal Medicine (Infectious Diseases)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
Infectious Diseases
300 Cedar St, TAC
New Haven, Connecticut 06519
United States
About
Copy Link
Titles
Associate Professor of Internal Medicine (Infectious Diseases)
Appointments
Infectious Diseases
Associate Professor on TermPrimary
Other Departments & Organizations
- All Institutions
- Cancer-Infectious Diseases (Cancer-ID) Program
- Infectious Diseases
- Internal Medicine
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Fellowship
- Ohio State University Medical Center (2009)
- Residency
- York Hospital (2007)
- MD
- University of Maryland School of Medicine, Internal Medicine Infectious Diseases (2004)
- PhD
- University of Maryland Baltimore Graduate School, Epidemiology (2002)
- BS
- University of Maryland College Park, Biochemistry (1992)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mark Lustberg's published research.
Publications Timeline
A big-picture view of Mark Lustberg's research output by year.
Maryam Lustberg, MD, MPH
Brian Clark, MD
66Publications
678Citations
Publications
2026
Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease
Weigel C, Klimaszewski H, Tounkara F, Addissie S, Schlotter S, Pray B, Dugan J, Haverkos B, Villagomez L, Lustberg M, Porcu P, Voorhees T, Ambinder R, Kenney S, Fingeroth J, Delecluse H, Caligiuri M, Alinari L, Bumgardner G, Oakes C, Baiocchi R. Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease. Blood Neoplasia 2026, 3: 100200. PMID: 41808730, PMCID: PMC12969294, DOI: 10.1016/j.bneo.2026.100200.Peer-Reviewed Original ResearchAltmetricConceptsRapid amplificationEpigenetic activationPromoter activityComplimentary DNADNA methylation lossTranscription start siteViral protein kinaseRNA expression analysisPTLD casesLymphoproliferative diseaseStart siteCpG dinucleotidesActive demethylationDNA methylationLong-term clinical outcome dataEBV-infected cell linesEpigenetic basisGene promoterMethylation levelsProtein kinaseExpression analysisSystemic lymphoproliferative diseaseClinical outcome dataLuciferase reporter analysisPromoter methylation
2025
Assessment of EBV DNA methlyation to guide antiviral use in EBV-associated lymphoma
Noel C, Weigel C, Klimaszewski H, Host K, Wu Y, Schlotter S, Ahmed E, Brooks E, Blachly J, Lustberg M, Voorhees T, Oakes C, Baiocchi R. Assessment of EBV DNA methlyation to guide antiviral use in EBV-associated lymphoma. Blood 2025, 146: 1752-1752. DOI: 10.1182/blood-2025-1752.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusDiffuse large B-cell lymphomaCell-free DNANK/T-cell lymphomaViral loadGroup 2Ganciclovir useCell lymphomaAssociated with disease entityCross-sectional study cohortEpstein-Barr virus viremiaGroup 1Subgroup 1aLarge B-cell lymphomaCpG sitesAssociated with favorable outcomesInclusion criteriaEBV-driven lymphomaPost-transplant lymphoproliferationsNK-cell lymphomasB-cell lymphomaEBV-associated lymphomasRetrospective chart reviewEpstein-Barr virus latencyGene expressionAnti-IL-5 Treatment Reduces Infection-Related Adverse Events: A Meta-Analysis of Phase 3 Clinical Trials
Lustberg M, Clark B. Anti-IL-5 Treatment Reduces Infection-Related Adverse Events: A Meta-Analysis of Phase 3 Clinical Trials. The Journal Of Allergy And Clinical Immunology In Practice 2025, 13: 1622-1631. PMID: 39947298, DOI: 10.1016/j.jaip.2025.01.037.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAnti-IL-5 therapyAnti-IL-5Lower respiratory tract infectionsPhase 3 clinical trialsRespiratory tract infectionsAdverse eventsTract infectionsPlacebo-controlled phase 3 clinical trialMeta-analysisInfection-related adverse eventsBacterial infectionsAnti-IL-5 treatmentC difficile infectionAssessment of adverse eventsClostridium difficile infectionPopulation of patientsInfectious diseasesInfluenza infectionMAb therapyDifficile infectionNon-serious eventsTherapyMultiple meta-analysesSerious eventsInfection
2024
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort
Nichols C, Lustberg M, Sobhanie M, Niermann L, Gordon M, Kman N, Parsons J, Conroy M, Dick M, Allen J, Reed E, Lehman J, Malvestutto C. Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort. Antiviral Therapy 2024, 29: 13596535241264694. PMID: 39066463, DOI: 10.1177/13596535241264694.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral AgentsCOVID-19COVID-19 Drug TreatmentDrug CombinationsEmergency Service, HospitalFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeConceptsMonoclonal antibody therapyFood and Drug AdministrationAntibody therapyClinical outcomesControl groupMild to moderate coronavirus diseasePost-COVID-19 diagnosisCOVID-19 diagnosisUntreated control cohortProgression to severe diseaseEmergency departmentHospital admissionDays of COVID-19 diagnosisDays post-diagnosisHigh-risk adultsED visitsModerate coronavirus diseaseLogistic regression analysisSingle-centerRetrospective studyClinical characteristicsMultivariate regression modelControl cohortOdds ratioDrug AdministrationA retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
McNally G, Aossey C, Wiczer T, Sinnott L, Lustberg M, Baiocchi R, Lustberg M. A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter? Leukemia & Lymphoma 2024, 65: 1110-1116. PMID: 38648546, DOI: 10.1080/10428194.2024.2340051.Peer-Reviewed Original ResearchCitationsAltmetricConceptsChemotherapy-induced peripheral neuropathyIncidence of chemotherapy-induced peripheral neuropathyHIV statusPeripheral neuropathyHIV-associated non-Hodgkin's lymphomaCohort studyDose-adjusted EPOCHNon-Hodgkin's lymphomaLong-term patient outcomesRetrospective cohort studyNon-HodgkinComprehensive cancer centerCancer CenterHIVPatientsNeuropathyPatient outcomesPropensity scoreLymphomaAdverse effectsIncidenceStatusRegimenVincristine
2023
Weight Gain in People with HIV: The Role of Demographics, Antiretroviral Therapy, and Lifestyle Factors on Weight
Patel Y, Doshi A, Levesque A, Lindor S, Moranville R, Okere S, Robinson D, Taylor L, Lustberg M, Malvestutto C. Weight Gain in People with HIV: The Role of Demographics, Antiretroviral Therapy, and Lifestyle Factors on Weight. AIDS Research And Human Retroviruses 2023, 39: 652-661. PMID: 37276145, DOI: 10.1089/aid.2023.0008.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIntegrase strand transfer inhibitorsFactors associated with weight gainAntiretroviral therapyRetrospective cohort studyTenofovir alafenamideOhio State University Wexner Medical CenterEffects of concurrent medicationsWeight gainStudy periodAntiretroviral therapy combinationsHistory of malignancyStrand transfer inhibitorsFollow-up periodWeight changeCombination therapyViral loadConcurrent medicationsWexner Medical CenterAdult PWHFollow-upMedical comorbiditiesPrimary outcomeMixed effects regression analysisSecondary outcomesTransfer inhibitorsTargeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease
Klimaszewski H, Weigel C, Addissie S, Schlotter S, Fode T, Dugan J, Haverkos B, Villagomez L, Lustberg M, Porcu P, Voorhees T, Caligiuri M, Oakes C, Bumgardner G, Baiocchi R. Targeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease. Blood 2023, 142: 4476. DOI: 10.1182/blood-2023-189618.Peer-Reviewed Original ResearchConceptsOverall survivalLymphoproliferative diseaseCell lymphomaCNS involvementEBV-PCRRetrospective reviewDiffuse large B-cell lymphomaTwo-year overall survivalLarge B-cell lymphomaPost-transplant lymphoproliferative diseaseRetrospective review of patientsPCR of cerebrospinal fluidResponse rateB-cell LPDsSecondary CNS involvementTwo-year OSHistory of immunosuppressionHigh-dose methotrexateB-cell lymphomaReview of patientsSystemic lymphoproliferative diseaseViral kinaseExpression of LMP1Follow-up timeOverall response rateFollicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein–Barr Virus Lymphoproliferative Disorder
Ahmed E, Lustberg M, Hale C, Sloan S, Mao C, Zhang X, Ozer H, Schlotter S, Smith P, Jeney F, Chan K, Harrington B, Weigel C, Brooks E, Klimaszewski H, Oakes C, Abebe T, Ibrahim M, Alinari L, Behbehani G, Shindiapina P, Caligiuri M, Baiocchi R. Follicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein–Barr Virus Lymphoproliferative Disorder. Cancers 2023, 15: 3046. PMID: 37297008, PMCID: PMC10252287, DOI: 10.3390/cancers15113046.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEBV-driven lymphoproliferative disordersPeripheral blood mononuclear cellsEpstein-Barr virusDonor peripheral blood mononuclear cellsRegulatory T cellsT cellsLymphoproliferative disordersAnalysis of CD4+ T cellsEngraftment of immunodeficient miceHealthy EBV-seropositive donorsMyeloid-derived suppressor cellsCD4+ T cellsEBV-seropositive donorsT follicular helperMemory B cellsInflammatory gene signatureLife-long persistenceBlood mononuclear cellsEBV+ donorsSuppressor cellsCTL proliferationEngrafted miceImmunocompromised patientsFollicular helperImmunodeficient mice
2022
Methylome Analysis of Epstein-Barr Virus with Nanopore Sequencing Reveals Viral State Dynamics
Weigel C, Kautto E, Ahmed E, Wu Y, Gregory C, Cleary A, Schlotter S, Brooks E, Lustberg M, Baiocchi R, Blachly J, Oakes C. Methylome Analysis of Epstein-Barr Virus with Nanopore Sequencing Reveals Viral State Dynamics. Blood 2022, 140: 8772-8773. DOI: 10.1182/blood-2022-159739.Peer-Reviewed Original ResearchP1244: ROLE OF SELECT T HELPER CELL MONONUCLEAR CELL SUBSETS PROMOTING EPSTEIN‐BARR VIRUS‐DRIVEN LYMPHOPROLIFERATIVE DISEASE IN THE HU‐PBL‐SCID MODEL
Ahmed E, Lustberg M, Hale C, Sloan S, Mao C, Zhang X, Ozer H, Schlotter S, Jeney F, Chan W, Harrington B, Weigel C, Alinari L, Oakes C, Abebe T, Behbehani G, Shindiapina P, Caligiuri M, Baiocchi R. P1244: ROLE OF SELECT T HELPER CELL MONONUCLEAR CELL SUBSETS PROMOTING EPSTEIN‐BARR VIRUS‐DRIVEN LYMPHOPROLIFERATIVE DISEASE IN THE HU‐PBL‐SCID MODEL. HemaSphere 2022, 6: 1129-1130. PMCID: PMC9429323, DOI: 10.1097/01.hs9.0000847840.97069.60.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Copy Link
Clinical Care
Copy Link
Overview
Mark Lustberg, MD, PhD, is an infectious disease specialist who focuses on managing infectious diseases, including HIV and AIDS.
As an associate professor of internal medicine at Yale School of Medicine, Dr. Lustberg researches innovative strategies in the field of infectious diseases.
Dr. Lustberg earned his medical degree from the University of Maryland School of Medicine and a doctorate in epidemiology from the University of Maryland, Baltimore, Graduate School. He then furthered his training by completing a residency at York Hospital and a fellowship at Ohio State University Medical Center.
Clinical Specialties
Infectious Diseases; HIV & AIDs Medicine
Fact Sheets
Sepsis
Learn More on Yale MedicineParasitic Diseases
Learn More on Yale MedicinePediatric Sepsis
Learn More on Yale MedicineEndocarditis
Learn More on Yale Medicine
Board Certifications
Infectious Diseases
- Certification Organization
- American Board of Internal Medicine
- Latest Certification Date
- 2022
- Original Certification Date
- 2019
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileGet In Touch
Copy Link
Contacts
Appointment Number
Mailing Address
Infectious Diseases
300 Cedar St, TAC
New Haven, Connecticut 06519
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.